Compare DexCom, Inc. (DXCM) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Tyson Foods, Inc. — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Tyson Foods, Inc. trades at $53.43 (market cap $18.41B). The key difference: DexCom, Inc. is the larger of the two by market cap, and Tyson Foods, Inc. pays a 3.9% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Tyson Foods, Inc. for 76 Days on average.
| DXCM | TSN | |
|---|---|---|
Market Cap | $31.86B | $18.41B |
Volume | 3,607,070 | 3,757,599 |
Sector | Health | Consumer Staples |
52-Week High | $92.34 | $68.75 |
52-Week Low | $54.84 | $50.47 |
Typical Hold Time | 62 Days | 76 Days |
Enterprise Value | $31.32B | $25.68B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.11, down 0.23% on the day, with a bearish technical signal but strong fundamental performance. The company reported Q2 2026 EPS of $0.70, beating expectations, and has shown consistent revenue growth, with 2025 revenue reaching $4.66 billion and net income of $836.3 million. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target. Recent news highlights growth opportunities in Type 2 diabetes care and key executive promotions.
The outlook for DXCM is positive due to robust earnings beats, expanding market opportunities, and strong institutional support. However, risks include competitive pressures, reimbursement challenges, and a high valuation with a P/E of 33.38. The stock presents a growth opportunity but requires monitoring of execution against these risks.
Tyson Foods (TSN) trades at $53.43, up 3.35% with mixed technical signals showing bullish overall but bearish moving averages. The company reported Q2 2026 EPS of $0.99, beating expectations, but faces challenges with thin 1.03% net margins and ongoing beef segment losses. Recent news highlights securities investigations and reduced 2026 revenue guidance, creating investor uncertainty despite institutional buying activity.
The stock presents a cautious opportunity with analyst consensus target of $65.40 (22% upside) but faces significant headwinds from margin pressure and legal scrutiny. Key risks include beef segment profitability, potential securities violations, and volatile cash flow patterns. Upside depends on operational improvements and resolution of ongoing investigations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
